Directory

>

Colin Hessel

avatar

Colin Hessel

Executive Vice President, Development Operations | Ambrx

United States

View contact details (it's free)

Colin Hessel

Summary

Colin Hessel is a seasoned drug development executive and biostatistician with a robust 25-year track record in the pharmaceutical industry, particularly in oncology. His leadership skills are complemented by a strong background in clinical trial design and regulatory strategy, having successfully led teams of over 200 professionals in the development of groundbreaking therapies. Colin played a pivotal role in the approval of cabozantinib across multiple indications, showcasing his expertise in navigating complex regulatory environments. His innovative spirit is evident in his invention of the 'trial in a trial' study design, aimed at enhancing clinical trial robustness. With a commitment to fostering transformational leadership, he is dedicated to building high-performing teams that align with organizational missions. Colin's academic foundation includes advanced degrees from the University of Southern California, further solidifying his expertise in biostatistics and clinical research. He is passionate about advancing oncology therapies and enhancing patient outcomes through rigorous data-driven strategies.

General

Specialist

Technical Background

Leadership Experience

Long-Term Tenure

Professional interests

Leadership Development

Emerging Technologies

Innovation

Organisational experience

Corporate Experience

Consulting Experience

Colin Hessel

Work Experience

company logo

Executive Vice President, Development Operations at

Ambrx

March 2023 - Present

company logo

Biostatistics & Drug Development Consultant at

Self-Employed

August 2022 - March 2023

company logo

Senior Vice President, Development Operations at

Exelixis

January 2016 - July 2022

company logo

Vice President, Development Operations at

Exelixis

January 2015 - January 2016

company logo

Vice President and Head, Biostatistics and Clinical Data Management at

Exelixis

January 2012 - January 2015

company logo

Executive Director & Head, Biostatistics and Clinical Data Management at

Exelixis

January 2009 - January 2012

company logo

Senior Director & Head, Biostatistics and Clinical Data Management at

Exelixis

January 2008 - January 2009

company logo

Director & Head, Biostatistics and Clinical Data Management at

Exelixis

April 2007 - January 2008

company logo

Associate Director, Biostatistics at

Telik

January 2005 - March 2007

company logo

Director, Biostatistics at

MedImmune

January 2002 - January 2004

company logo

Associate Director, Biostatistics at

MedImmune

January 1998 - January 2002

company logo

Biostatistician at

Amgen

January 1996 - January 1998

Logos provided by Logo.dev

Colin Hessel

Education

Keck School of Medicine of the University of Southern California, Master Of Science

January 1970 - January 1970

Keck School of Medicine of the University of Southern California, Master Of Science

January 1970 - January 1970

University of California, Irvine, Bachelors

January 1970 - January 1970

Frequently Asked Questions about Colin Hessel

What is Colin Hessel email address?

Colin Hessel's primary email address is ************@exelixis.com. To view the full verified email and additional contact details, sign up for free with Muraena.

What company does Colin Hessel work for?

Colin Hessel is a Executive Vice President, Development Operations at Ambrx, a company specializing in Commercial physical research.

Where Colin Hessel graduated from?

Colin Hessel holds a degree in Masters from Keck School of Medicine of the University of Southern California.

How can I directly contact Colin Hessel?

To contact Colin Hessel directly, you can use the email address ************@exelixis.com. Complete contact information is available upon registration with Muraena.

Who is Colin Hessel?

Colin Hessel is a seasoned drug development executive and biostatistician with a robust 25-year track record in the pharmaceutical industry, particularly in oncology. His leadership skills are complemented by a strong background in clinical trial design and regulatory strategy, having successfully led teams of over 200 professionals in the development of groundbreaking therapies. Colin played a pivotal role in the approval of cabozantinib across multiple indications, showcasing his expertise in navigating complex regulatory environments. His innovative spirit is evident in his invention of the 'trial in a trial' study design, aimed at enhancing clinical trial robustness. With a commitment to fostering transformational leadership, he is dedicated to building high-performing teams that align with organizational missions. Colin's academic foundation includes advanced degrees from the University of Southern California, further solidifying his expertise in biostatistics and clinical research. He is passionate about advancing oncology therapies and enhancing patient outcomes through rigorous data-driven strategies.

Colin`s contact details

mail

************@exelixis.com

************@ambrx.com

Colleagues

avatar
Shawn Shao-Hui Zhang

Chief Scientific Officer and GM China

avatar
Adair Turner Ms Rac

Executive Director, Regulatory Affairs

avatar
Renu Vaish

Chief Regulatory Officer

Lawson Macartney

President and Chief Executive Officer

avatar
Sandra Aung

Executive Vice President; Head of Clinical

avatar
Sonja Nelson

Chief Financial Officer

avatar
Mysore Ramprasad

Vice President, Pharmaceutical & Analytical Development at Ambrx, a Johnson & Johnson Co.

avatar
Johnathan Maher

VP, Head of Medical Affairs

View Contact details (it's free)
Request Profile Removal